Myelodysplastic Syndrome (MDS) Treatments
Find Myelodysplastic Syndrome (MDS) Treatments
Medications for Myelodysplastic Syndrome (MDS)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Myelodysplastic Syndrome (MDS).
Found 6 Approved Drugs for Myelodysplastic Syndrome (MDS)
AzaCITIDine
Brand Names
Onureg, Vidaza
AzaCITIDine
Brand Names
Onureg, Vidaza
Form: Injection, Tablet
Method of administration: Subcutaneous, Intravenous, Oral
FDA approval date: July 05, 2004
Classification: Nucleoside Metabolic Inhibitor
ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy ( 1 ).
Inqovi
Generic Name
Decitabine
Inqovi
Generic Name
Decitabine
Form: Injection, Tablet, Kit
Method of administration: Oral, Intravenous
FDA approval date: July 11, 2013
Classification: Nucleoside Metabolic Inhibitor
INQOVI is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, indicated: For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Revlimid
Generic Name
Lenalidomide
Revlimid
Generic Name
Lenalidomide
Form: Capsule
Method of administration: Oral
FDA approval date: December 27, 2005
Classification: Thalidomide Analog
REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone.
Reblozyl
Generic Name
Luspatercept
Reblozyl
Generic Name
Luspatercept
Form: Injection
Method of administration: Subcutaneous
FDA approval date: November 08, 2019
Classification: Erythroid Maturation Agent
REBLOZYL is an erythroid maturation agent indicated for the treatment of: Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Rytelo
Generic Name
Imetelstat
Rytelo
Generic Name
Imetelstat
Form: Injection
Method of administration: Intravenous
FDA approval date: June 06, 2024
Classification: Oligonucleotide Telomerase Inhibitor
RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). ( 1 )
Showing 1-5 of 6
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances